Goldman Sachs
ARIA

Goldman Sachs’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Goldman Sachs’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,394,100
Closed -$17.3M – 7244
2016
Q4 		$17.3M Sell
1,394,100
-1,968,082
-59% -$23.7M ﹤0.01% 2063
2016
Q3 		$46M Buy
3,362,182
+1,592,947
+90% +$16M 0.01% 1270
2016
Q2 		$13.1M Buy
1,769,235
+1,178,773
+200% +$8.84M ﹤0.01% 2107
2016
Q1 		$3.77M Buy
590,462
+206,616
+54% +$1.16M ﹤0.01% 2930
2015
Q4 		$2.4M Sell
383,846
-214,680
-36% -$1.41M ﹤0.01% 3468
2015
Q3 		$3.5M Sell
598,526
-201,952
-25% -$1.56M ﹤0.01% 3216
2015
Q2 		$6.62M Buy
800,478
+299,575
+60% +$2.65M ﹤0.01% 2694
2015
Q1 		$4.13M Sell
500,903
-338,145
-40% -$2.5M ﹤0.01% 3087
2014
Q4 		$5.76M Sell
839,048
-4,209
-0.5% -$26.3K ﹤0.01% 2863
2014
Q3 		$4.55M Buy
843,257
+351,794
+72% +$2.05M ﹤0.01% 3112
2014
Q2 		$3.13M Buy
491,463
+89,898
+22% +$618K ﹤0.01% 3533
2014
Q1 		$3.24M Sell
401,565
-517,781
-56% -$4.03M ﹤0.01% 3516
2013
Q4 		$6.27M Sell
919,346
-7,203,784
-89% -$38.9M ﹤0.01% 2822
2013
Q3 		$149M Buy
8,123,130
+1,554,560
+24% +$30.2M 0.06% 402
2013
Q2 		$115M Buy
+6,568,570
New +$116M 0.04% 491

Other funds holding ARIA

FPF
FNY Partners Fund New York $185M AUM 32.58% 1-Year Est. Return

Goldman Sachs's ARIA Position: Q1 2017 in Review

Goldman Sachs sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 1,394,100 shares — an estimated $17.3M sold.

Goldman Sachs first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $149M in Q3 2013. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

  • Goldman Sachs reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Goldman Sachs sold 1,394,100 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $17.3M.
  • Goldman Sachs first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
  • Goldman Sachs's Ariad Pharmaceuticals Inc position peaked at $149M in Q3 2013.
  • 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on Goldman Sachs's 13F filing for Q1 2017, filed 15 May 2017.